Ponnari Gottipati

Cancer Research UK — United Kingdom

Medicine · Health Sciences

8h-index1.2kcitations40works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(23), Cell Image Analysis Techniques(12), Cancer Research and Treatments(10), DNA Repair Mechanisms(9), CRISPR and Genetic Engineering(7)

Publications40 total

Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 5 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 3 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 1 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure Legends 1-4 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 2 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 6 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 3 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 4 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 4 from Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Thomas Helleday(40), Adrian L. Harris(21), Ivaylo Stoimenov(21), Natalia Issaeva(20), Kate Sleeth(20), Ricky A. Sharma(20), Huw D. Thomas(19), Tatjana Djurenovic(19), Janneke E. Jaspers(19), Suzanne Kyle(19), Nicholas Pedley(19), Rafal Zur(19), Vicky Chatzakos(19), Evan A. Mulligan(19), Cecilia Lundin(19), Evgenia Gubanova(19), Ariena Kersbergen(19), Sven Rottenberg(19), Nicola J. Curtin(19), Isabel M. Pires(14)